Study Summary
This trial is for patients with 1-6 brain metastases who will receive neo-adjuvant stereotactic radiosurgery.
Eligible Conditions
- Metastatic Brain Tumors
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 5 Secondary · Reporting Duration: 5 years
1 year
Radiation toxicity
leptomeningeal disease
local control
2 years
overall survival
progression-free survival
5 years
Survival
Trial Safety
Safety Progress
Trial Design
0 Treatment Group
30 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years
Who is running the clinical trial?
University Health Network, TorontoLead Sponsor
1,380 Previous Clinical Trials
473,409 Total Patients Enrolled
David Shultz, MDPrincipal InvestigatorUniversity Health Network, Toronto
Eligibility Criteria
Age 18+ · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments